2026-09-21T08:50:38Zhttps://wakespace.lib.wfu.edu/server/oai/request

oai:null:10339/641732026-09-02T16:32:23Zcom_10339_14934col_10339_38132

Deng, Guorui 2017-01-14T09:35:18Z 2018-01-13T09:30:09Z 2016 https://wakespace.lib.wfu.edu/handle/10339/64173 Breast cancer remains a devastating disease, negatively impacting the lives of many women worldwide. In the United States, 40,450 women succumbed to breast cancer in 2015, with an estimated 247,000 new cases being diagnosed in 2016. Approximately 15% of all breast cancer cases will be classified as triple negative breast cancer (TNBC), an aggressive form of breast cancer characterized by the lack of estrogen and progesterone receptors as well as normal expression of the human epidermal growth factor receptor 2 (HER2). These cellular properties thereby exclude patients diagnosed with TNBC from the benefits of current targeted agents. The aggressive nature of TNBC coupled with the lack of effective targeted therapies contribute to a greater patient mortality rate when compared to other breast cancer subtypes, underscoring a crucial need for novel development of actionable targets for this patient population. en Wake Forest University angiotensin-(1-7) c-met triple negative breast cancer REGULATION OF C-MET RECEPTOR TYROSINE KINASE SIGNALING BY ANGIOTENSIN-(1-7) IN TRIPLE NEGATIVE BREAST CANCER Dissertation Tallant, Elisabeth A Metheny-Barlow, Linda Miller, Lance D Singh, Ravi N Cancer Biology 2018-01-13 open.access